Protara Therapeutics logo
Protara Therapeutics
TARA | NASDAQ
Chart Builder DCF Calculator
$2.38
-$0.15 (-5.93%)
At close: Nov 16, 2026, 4:00 PM ET
$2.42
+$0.04 (+1.68%)
After-hours: Nov 16, 2026, 7:30 PM ET

Protara Therapeutics Company Profile

Company profile explained

Company Profile

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.

Key Executives

Name Position
Jesse Shefferman Co-founder, Chief Executive Officer, President & Director
Patrick Fabbio Chief Financial Officer
Shane Williams Chief People Officer
Carla Beckham Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist
Hannah Fry Vice President, Principal Accounting Officer & Controller
Jacqueline Zummo Co-Founder, Chief R&D Officer
Justine O'Malley Senior Vice President of Investor Relations & Corporate Affairs
Mary J. Grendell General Counsel & Corporate Secretary
Neal D. Shore Medical Director of START Carolinas/ Carolina Urologic Research Center
William Conkling Chief Commercial Officer

Latest SEC Filings

Date Type Title
Aug 13, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 S-8 Filing
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
Jul 07, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 01, 2026 4 Filing
Jun 29, 2026 8-K Current Report
Jun 16, 2026 4 Filing
Jun 16, 2026 4 Filing
Jun 16, 2026 4 Filing
View All SEC Filings ➞
Protara Therapeutics
Protara Therapeutics logo
Country United States
IPO Date Oct 22, 2014
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Jesse Shefferman

Contact Details

345 Park Avenue South New York City, New York 10010 United States

Stock Details

Ticker Symbol TARA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001359931
CUSIP Number 74365U107
ISIN Number US74365U1079
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.